GoldBamboo.com - Knowledge is strong medicine
  

Zactima offers chance of progression free survival advantage for lung cancer patients - News


  Not Signed In - Sign In / Register




General Topics A-Z

Zactima offers chance of progression free survival advantage for lung cancer patients

Sun, 10 Jul 2005 06:00 PM EST

... First inhibitor of VEGF* and EGF** signalling to show anti-tumour activity both as monotherapy and in combination with chemotherapy - AstraZeneca today reported new findings from two Phase II studies, Trials 003 and 006, in the 2nd-line treatment of NSCLC, with ZD6474 (ZACTIMA™), its novel selective inhibitor of key signalling pathways in cancer... click link for more info. ...

Related Topics

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

GoldBambooTM

Your Integrative Health and Wellness Resource

August 30, 2008


Page Updated: June 12, 2007
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.